Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Bronchial Leiomyoma Market Research Report Information By Site (Bronchi, Trachea), Diagnosis (Imaging, Blood Sampling, Biopsy), Treatment (Surgery, Bronchoscopy), End User (Hospitals & Clinics, Academic Institutes, Research Organization) - Global Forecast till 2030


ID: MRFR/Pharma/3418-HCR | 90 Pages | Author: Rahul Gotadki| May 2024

Bronchial Leiomyoma Market Scenario:


The bronchial leiomyoma market is expected to reach USD 11,481.38 Million by 2030 at 8.90% CAGR during the forecast period 2022-2030.A bronchial leiomyoma is a rare form of lung tumor, which affects the lower respiratory tract tissues including bronchi, trachea, and other lung tissues. Bronchial leiomyoma constitutes approximately 33%-45% of respiratory system leiomyoma. Mostly, bronchial leiomyoma arises from the smooth muscle tissue lining of the bronchi and grow as solitary tumors being attached to the sides of the bronchi.  With the increasing prevalence of the lung cancer, the cases of the bronchial leiomyoma are estimated to increase, which is likely to drive the market growth during the forecast period 2017-2023.  In 2017, according to the American Cancer Society, about 222,500 new cases of lung cancer are reported leading to 155,870 deaths. Moreover, increasing per capita healthcare expenditure, developing healthcare sector are expected to boost the market growth during the forecasted period. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. Moreover, the per capita healthcare expenditure of the U.S. was about USD 9,990 within the same year. However, the complexity of diagnosis and treatment along with the lack of awareness of the disease may restrain the Bronchial Leiomyoma market growth during the forecast period. 


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1:- Bronchial leiomyoma market share, by region Bronchial Leiomyoma Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The bronchial leiomyoma market is segmented on the basis of the site, diagnosis, treatment, and end users.


On the basis of the site, the market is segmented into bronchi, trachea, and others.


On the basis of the diagnosis, the market is segmented into imaging, blood sampling, biopsy, and others. The imaging segment is sub-segmented into X-rays, CT scan, PET scan, and others. The blood sampling segment is sub-segmented into liver function test, thyroid profiling, renal function test, and others. 


On the basis of the treatment, the market is segmented into surgery, bronchoscopy, and others.


On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others. 


Regional Analysis


The Americas dominate the bronchial leiomyoma market owing to a well-developed healthcare sector. Additionally, increasing number of patients, increasing healthcare expenditure have boosted the growth of the Americas market. Moreover, the presence of the global players like Eli Lilly and Company., Pfizer Inc., and GlaxoSmithKline Plc. and developed economies like the U.S. and Canada within the region fuel the market growth.


Europe is the second largest bronchial leiomyoma market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, and government support for research & development drive the European market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population and continuously developing economies like India and China. Moreover, the untapped market of the region has huge opportunities for the Bronchial Leiomyoma Market growth.


On the other hand, the Middle East & Africa owns the least share of the bronchial leiomyoma market due to the presence of poor economy, especially, in the African region, which has low per capita income. Moreover, stringent government policies may restrain the growth of the market in the African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology Global bronchial leiomyoma market


Sources: WHO, annual reports, press release, white paper, and company presentation 


 


Key players in the bronchial leiomyoma market: Hoffmann-La Roche Ltd (Europe), AstraZeneca (Europe), Eli Lilly and Company. (U.S.), Sanofi (Europe), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.S.), ArQule. (U.S.), Boehringer Ingelheim GmbH (Europe), and others.

Report Attribute/Metric Details
  Market Size USD 11,481.38 Million
  CAGR   8.90% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered By Site, Treatment, End Users
  Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors Hoffmann-La Roche Ltd (Europe), AstraZeneca (Europe), Eli Lilly and Company. (U.S.), Sanofi (Europe), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.S.), ArQule. (U.S.), Boehringer Ingelheim GmbH (Europe), and others.
  Key Market Opportunities Develop improved diagnostic techniques for early detection of bronchial leiomyoma
  Key Market Drivers Innovations in diagnostic techniques
 

Frequently Asked Questions (FAQ) :

bronchial leiomyoma market is projected to grow at approximately 8.90% CAGR during the assessment period (2022-2030).

Increasing per capita healthcare expenditure and developing healthcare sector are major tailwinds pushing the growth of the global bronchial leiomyoma market.

Complexity of diagnosis & treatment and the lack of awareness regarding the disease are major growth impeders for the global bronchial leiomyoma market.

North America holds the largest share in the global bronchial leiomyoma market, followed by Europe and the Asia Pacific, respectively.

Hoffmann-La Roche Ltd (Europe), Eli Lilly and Company. (U.S.), AstraZeneca (Europe), Sanofi (Europe), Pfizer Inc. (U.S.), ArQule. (U.S.), GlaxoSmithKline Plc. (U.S.), and Boehringer Ingelheim GmbH (Europe), are some of the top players operating in the global bronchial leiomyoma market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.